Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
COMPASS Pathways plcCMPS-2.090.001.56-0.53-64.68%-40.17%55.69$4.41$15.6124,786$4.41

Detail of COMPASS Pathways plc

 
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Employees
186
Industry
Medical Care Facilities
Sector
Healthcare
Market cap
$302M

Company details

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc
CMPS • XNGS • US
$4.41
-6.11 (-58.08%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$2.11
Margin profit
0.00%
52 week low
$3.315
52 week high
$12.37
50-day simple moving average
$4.29
200-day simple moving average
$4.41
Percent held by insiders
16.40%
Percent held by institutions
45.12%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
CMPS -57.68%
eps change
CMPS 0.00%